Top section
Top section
The era of pure-play private equity is over. Banks are pulling different divisions together to serve the complex needs of global asset managers
Specialist moves after 18 years in the market
New dangers are making deals harder to do, but pricing for the haves is still tight
More articles
More articles
More articles
-
US CLO issuers are rushing to market, filling the pipeline and looking to price and close a flurry of deals before the market effectively shuts ahead of risk retention implementation. -
The ECB’s announcement it was planning leveraged lending rules for the banks it supervises has been polarising, confusing, and often emotional. But the market will come to appreciate it in time.
-
US drugs specialist Catalent Pharma on Tuesday began offering its debut euro bond to investors as it sought funding for its acquisition of peers Pharmatek and Accucaps.
-
Elysium Healthcare, a portfolio of 22 UK mental healthcare facilities being divested by Acadia Group, held a lender meeting on Thursday for £240m of loans following its £320m buyout by BC Partners.
-
Morpho leads the way for European leveraged loan issuance this week, the largest of five deals in the market and the largest euro leveraged buyout of the year by some distance.
-
The credit arms of private equity firms CVC and EQT have joined efforts to provide Paymentsense, the UK card payment services firm, with a refinancing unitranche facility — a form of financing that could increase next year.
Sub-sections
shared comment list
